Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Akari Therapeutics PLC

Healthcare US AKTX

14.985USD
0.35(2.43%)

Last update at 2026-06-03T20:00:00Z

Day Range

13.0515.85
LowHigh

52 Week Range

3.2559.60
LowHigh

Fundamentals

  • Previous Close 14.63
  • Market Cap6.80M
  • Volume59097
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.08100M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -18.30100M -19.79100M -10.00800M -17.74806M -17.42424M
Minority interest - - - - -
Net income -17.29800M -19.79100M -10.00800M -6.97225M -17.60686M
Selling general administrative 9.28M 9.66M 11.36M 13.53M 8.08M
Selling and marketing expenses - - 11.34M - -
Gross profit - -0.01400M -0.00400M - -
Reconciled depreciation 0.00000M 0.01M 0.00400M 0.00371M 0.00413M
Ebit - -19.54700M -16.80600M -23.08821M -17.21414M
Ebitda -17.27500M -19.53300M -16.80200M -28.52016M -17.01679M
Depreciation and amortization - 0.01M 0.00400M -5.43196M 0.20M
Non operating income net other - - - - -
Operating income -17.27500M -21.64300M -16.80600M -23.08821M -17.21414M
Other operating expenses 17.27M 21.64M 16.81M 23.09M 17.21M
Interest expense 0.95M 0.24M 0.00000M -5.34015M 0.21M
Tax provision -1.00300M 0.00000M - -2.47200M -
Interest income 0.00100M 0.00800M 0.08M 0.05M 0.01M
Net interest income -0.94800M -0.23600M 0.08M 0.05M 0.01M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.00300M - - -10.77581M 0.18M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 17.27M 21.64M 16.81M 23.89M 17.21M
Cost of revenue - 0.01M 0.00400M - -
Total other income expense net -1.02600M 1.85M 6.80M 5.34M -0.21010M
Discontinued operations - - - - -
Net income from continuing ops -17.29800M -19.79100M -10.00800M -17.74806M -17.42424M
Net income applicable to common shares - - - - -17.42424M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 47.89M 50.56M 4.36M 13.83M 11.65M
Intangible assets 34.00M 39.18M 0.01M 0.02M 0.02M
Earning assets - - - - -
Other current assets 0.26M 0.15M 0.50M 0.10M 0.09M
Total liab 19.56M 28.33M 4.58M 12.04M 6.09M
Total stockholder equity 28.33M 22.23M -0.22900M 1.79M 5.55M
Deferred long term liab - - - - -
Other current liab 2.83M 4.24M 2.91M 11.09M 4.30M
Common stock - 5.32M 1.32M 0.74M 0.48M
Capital stock 0.00000M 5.32M - 0.74M 0.48M
Retained earnings -264.55000M -247.25200M -227.46100M -217.45311M -199.70505M
Other liab - - - - -
Good will 8.43M 8.43M - - -
Other assets - - - - -
Cash 5.20M 2.60M 3.85M 13.25M 9.36M
Cash and equivalents - - - - -
Total current liabilities 12.35M 19.91M 4.58M 12.04M 6.09M
Current deferred revenue - - - - -
Net debt -4.44900M 0.66M -3.84500M -13.24995M -9.36127M
Short term debt 0.75M 3.26M - - -
Short long term debt 0.75M 3.26M - - -
Short long term debt total 0.75M 3.26M - - -
Other stockholder equity 293.66M 264.90M 174.75M 219.27M 205.32M
Property plant equipment - - - - -
Total current assets 5.46M 2.95M 4.34M 13.81M 11.63M
Long term investments - - - - -
Net tangible assets - - - - 5.53M
Short term investments - - - - -
Net receivables - 0.20M - 2.95M -
Long term debt - - - - -
Inventory - - - -2.48576M -
Accounts payable 8.77M 12.41M 1.67M 0.95M 1.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.78200M -0.73800M 51.15M -0.77084M -0.54097M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 0.01M - -
Deferred long term asset charges - - - - -
Non current assets total 42.43M 47.61M 0.01M 0.02M 0.02M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.38M 0.00000M - -
Change to liabilities - - - - -0.24131M
Total cashflows from investing activities - 0.38M - - -
Net borrowings 1.05M -0.85500M 0.00000M - -
Total cash from financing activities 13.17M 10.99M 7.02M 25.29M 14.29M
Change to operating activities - - - - -1.74226M
Net income -17.29800M -19.79100M -10.00800M -17.74806M -17.42424M
Change in cash 2.60M -1.18600M -9.40500M 3.89M -4.69451M
Begin period cash flow 2.66M 3.85M 13.25M 9.36M 14.06M
End period cash flow 5.26M 2.66M 3.85M 13.25M 9.36M
Total cash from operating activities -10.56800M -12.55200M -16.43200M -21.50452M -18.84653M
Issuance of capital stock 10.72M 11.81M 7.02M 25.19M 14.29M
Depreciation 0.00000M 0.01M 0.00400M 0.00371M 0.00413M
Other cashflows from investing activities - 0.38M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - 1.70M -
Sale purchase of stock - - - - -
Other cashflows from financing activities 13.17M 0.03M 0.00400M 0.09M -
Change to netincome - - - - 0.56M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.40400M 6.54M -0.86600M 0.82M -1.98357M
Stock based compensation 2.89M 2.25M 1.15M 0.74M 0.31M
Other non cash items 5.33M -1.55900M -6.71200M -5.31717M 0.24M
Free cash flow -10.56800M -12.55200M -16.43200M -21.50452M -18.84653M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AKTX
Akari Therapeutics PLC		 0.35 2.43% 14.98 - - 478368.50 0.23 400346.36 -0.0639
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.

Akari Therapeutics PLC

22 Boston Wharf Road, Boston, MA, United States, 02210

Key Executives

Name Title Year Born
Dr. Ray Prudo-Chlebosz M.D. Exec. Chairman 1945
Dr. Torsten Hombeck Chief Financial Officer 1970
Ms. Rachelle Suzanne Jacques Pres, CEO & Director 1971
Ms. Melissa Bradford-Klug Chief Operating Officer NA
Dr. Miles Nunn Chief Scientific Officer NA
Dr. John F. Neylan III, M.D. Exec. VP & Chief Medical Officer 1953
Annie Mack Financial Controller NA
Ms. Rachelle Suzanne Jacques President, CEO & Director 1971
Ms. Wendy F. DiCicco CPA Interim Chief Financial Officer 1967
Ms. Melissa Bradford-Klug Chief Operating Officer 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.